{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:55:02Z","timestamp":1793382902019,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2024SF-ZDCYL-03\\u201307"],"award-info":[{"award-number":["2024SF-ZDCYL-03\\u201307"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2024NC-ZDCYL-04\\u201316"],"award-info":[{"award-number":["2024NC-ZDCYL-04\\u201316"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GK202205010"],"award-info":[{"award-number":["GK202205010"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GK202205001"],"award-info":[{"award-number":["GK202205001"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81373201"],"award-info":[{"award-number":["81373201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.phymed.2025.157532","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:45:37Z","timestamp":1762541137000},"page":"157532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Escin inhibits PD-L1 expression by suppressing the p38 MAPK\/ERK signalling pathways and synergistically enhances PD-1 inhibitor efficacy in hepatocellular carcinoma"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0638-9266","authenticated-orcid":false,"given":"Yue","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5281-9499","authenticated-orcid":false,"given":"Zihan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvash Chandra","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5125-2417","authenticated-orcid":false,"given":"Changfeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenglu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9875-9821","authenticated-orcid":false,"given":"Xiaochang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2025.157532_bib0001","article-title":"New frontiers in liver resection for hepatocellular carcinoma","volume":"2","author":"Allaire","year":"2020","journal-title":"JHEP. Rep."},{"key":"10.1016\/j.phymed.2025.157532_bib0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phymed.2025.157532_bib0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phymed.2025.157532_bib0004","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2025.157532_bib0005","article-title":"Therapy of primary liver cancer","volume":"1","author":"Feng","year":"2020","journal-title":"Innovation"},{"key":"10.1016\/j.phymed.2025.157532_bib0006","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial","volume":"69","author":"Finn","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2025.157532_bib0007","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phymed.2025.157532_bib0008","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phymed.2025.157532_bib0009","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","article-title":"PD-L1 degradation pathway and immunotherapy for cancer","volume":"11","author":"Gou","year":"2020","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.phymed.2025.157532_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202403858","article-title":"Tumor microenvironment-responsive nanocapsule delivery CRISPR\/Cas9 to reprogram the immunosuppressive microenvironment in Hepatoma carcinoma","volume":"11","author":"He","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.phymed.2025.157532_bib0011","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/tox.23988","article-title":"Escin-sorafenib synergy up-regulates LC3-II and p62 to induce apoptosis in hepatocellular carcinoma cells","volume":"39","author":"Hussain","year":"2024","journal-title":"Env. Toxicol."},{"key":"10.1016\/j.phymed.2025.157532_bib0012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phymed.2025.157532_bib0013","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jtho.2019.02.004","article-title":"The combination of MEK inhibitor with immunomodulatory antibodies targeting programmed death 1 and programmed death ligand 1 results in prolonged survival in Kras\/p53-driven lung cancer","volume":"14","author":"Lee","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phymed.2025.157532_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112592","article-title":"Escin alleviates cerebral ischemia-induced intestinal pyroptosis via the GR-dependent p38 MAPK\/NF-\u03bab signaling and NLRP3 inflammasome activation","volume":"138","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phymed.2025.157532_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1070961","article-title":"PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phymed.2025.157532_bib0016","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phymed.2025.157532_bib0017","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phymed.2025.157532_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123026","article-title":"MAPK\/ERK signaling pathway in hepatocellular carcinoma","volume":"13","author":"Moon","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phymed.2025.157532_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092053","article-title":"The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities","volume":"13","author":"Neophytou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phymed.2025.157532_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phymed.2025.157532_bib0021","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.8006","article-title":"Escin inhibits angiogenesis by suppressing interleukin\u20118 and vascular endothelial growth factor production by blocking nuclear factor\u2011\u03bab activation in pancreatic cancer cell lines","volume":"45","author":"Omi","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phymed.2025.157532_bib0022","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jhep.2020.05.028","article-title":"Peptide SMIM30 promotes HCC development by inducing SRC\/YES1 membrane anchoring and MAPK pathway activation","volume":"73","author":"Pang","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2025.157532_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413311","article-title":"Immune regulatory processes of the tumor microenvironment under malignant conditions","volume":"22","author":"Pansy","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2025.157532_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13046-025-03368-w","article-title":"LINC02167 stabilizes KSR1 mRNA in an m(5)C-dependent manner to regulate the ERK\/MAPK signaling pathway and promotes colorectal cancer metastasis","volume":"44","author":"Qi","year":"2025","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"key":"10.1016\/j.phymed.2025.157532_bib0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phymed.2025.157532_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153723","article-title":"Cancer immunotherapy: challenges and limitations","volume":"229","author":"Taefehshokr","year":"2022","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.phymed.2025.157532_bib0027","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/jpet.110.165498","article-title":"Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3\/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells","volume":"334","author":"Tan","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phymed.2025.157532_bib0028","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.7150\/thno.41498","article-title":"ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma","volume":"10","author":"Tong","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.phymed.2025.157532_bib0029","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.intimp.2017.03.015","article-title":"Primary and acquired resistance to PD-1\/PD-L1 blockade in cancer treatment","volume":"46","author":"Wang","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phymed.2025.157532_bib0030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.canlet.2018.10.015","article-title":"Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin \u03b23-p38 MAPK signalling","volume":"442","author":"Wen","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2025.157532_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107733","article-title":"Traditional Chinese medicine and natural products in management of hepatocellular carcinoma: biological mechanisms and therapeutic potential","volume":"215","author":"Xun","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phymed.2025.157532_bib0032","article-title":"Loss of ESRP2 activates TAK1-MAPK signaling through the fetal RNA-splicing program to promote hepatocellular carcinoma progression","volume":"11","author":"Yan","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.phymed.2025.157532_bib0033","doi-asserted-by":"crossref","first-page":"300","DOI":"10.17998\/jlc.2023.08.27","article-title":"Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes","volume":"23","author":"Yoon","year":"2023","journal-title":"J. liver cancer"},{"key":"10.1016\/j.phymed.2025.157532_bib0034","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1111\/cas.15741","article-title":"GNB1 promotes hepatocellular carcinoma progression by targeting BAG2 to activate P38\/MAPK signaling","volume":"114","author":"Zhang","year":"2023","journal-title":"Cancer Sci."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325011687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325011687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:28:43Z","timestamp":1773325723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711325011687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"alternative-id":["S0944711325011687"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2025.157532","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Escin inhibits PD-L1 expression by suppressing the p38 MAPK\/ERK signalling pathways and synergistically enhances PD-1 inhibitor efficacy in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2025.157532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157532"}}